Compare GRNQ & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRNQ | ONCO |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | Malaysia | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.6M | 3.0M |
| IPO Year | 2014 | 2021 |
| Metric | GRNQ | ONCO |
|---|---|---|
| Price | $10.35 | $0.66 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 123.2K | ★ 417.5K |
| Earning Date | 05-13-2026 | 06-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 22.80 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,673,997.00 | $815,371.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 24.55 | N/A |
| 52 Week Low | $1.04 | $0.09 |
| 52 Week High | $22.70 | $6.73 |
| Indicator | GRNQ | ONCO |
|---|---|---|
| Relative Strength Index (RSI) | 46.91 | 42.18 |
| Support Level | $1.51 | $0.61 |
| Resistance Level | $14.40 | $1.01 |
| Average True Range (ATR) | 2.65 | 0.09 |
| MACD | -0.79 | 0.00 |
| Stochastic Oscillator | 4.34 | 12.78 |
Greenpro Capital Corp operates and provides business solution services to small and medium-sized businesses located in Southeast Asia and East Asia, with a focus on Hong Kong, China, and Malaysia, and in Thailand and Taiwan. Its range of services includes cross-border business solutions, record management services, and accounting outsourcing services. Cross-border business services include other services, tax planning, trust, & wealth management. Its segments include the Service business engaged in the provision of corporate advisory & business solution services; the Real estate business segment engaged in trading or leasing of commercial real estate properties in Hong Kong & Malaysia; & the Digital business segment engaged in the provision of digital platform & trading of digital assets.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.